organization · Reporting owner
SV LIFE SCIENCES FUND IV, L.P.
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ENTELLUS MEDICAL INCENTL · Entity 16119 | 10% owner | January 31, 2017 | February 02, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ENTELLUS MEDICAL INC
Report date January 31, 2017 · Filed February 02, 2017
Jointly reported with SVLSF IV, LLC, INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P., INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P., SV LIFE SCIENCES FUND IV STRATEGIC PARTNERS, L. P., INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.001 par valueSEC Table I · non-derivative | IndirectBy ILSF LP1 | 1,091,166 |
Reported balance
After 2017-01-31 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2017-01-31 · Sale · Disposed 220,431 · Balance 1,091,166 F1: Represents a public offering price of $17.00 per share before underwriting discounts and commissions pursuant to an Underwriting Agreement dated January 25, 2017, which offering closed on January 31, 2017. F2: International Life Sciences Fund III (GP), L.P. ("Fund III GP") is the general partner of each of: (i) International Life Sciences Fund III (LP1), L.P. ("ILSF LP1"), (ii) International Life Sciences Fund III Co-Investment, L.P. ("ILSF Co-Invest") and (iii) International Life Sciences Fund III Strategic Partners, L.P. ("ILSF Strategic" and collectively, the "Fund III Entities"). ILSF III, LLC (the "ILSF General Partner") is the general partner of Fund III GP and, through an investment committee comprised of James Garvey, Kate Bingham, Eugene D. Hill, III and Michael Ross controls voting and investment decisions over the Issuer's shares held by the Fund III Entities by majority vote. F3: Each member of the investment committee of ILSF General Partner disclaims beneficial ownership over the Shares held by the Fund III Entities except to the extent of any pecuniary interest therein. Each of ILSF General Partner and Fund III GP disclaim beneficial ownership over the Shares held by the Fund III Entities except to the extent of their respective pecuniary interest therein. |
| Common Stock, $0.001 par valueSEC Table I · non-derivative | IndirectBy ILSF Co-Invest | 12,947 |
Reported balance
After 2017-01-31 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2017-01-31 · Sale · Disposed 2,615 · Balance 12,947 F1: Represents a public offering price of $17.00 per share before underwriting discounts and commissions pursuant to an Underwriting Agreement dated January 25, 2017, which offering closed on January 31, 2017. F2: International Life Sciences Fund III (GP), L.P. ("Fund III GP") is the general partner of each of: (i) International Life Sciences Fund III (LP1), L.P. ("ILSF LP1"), (ii) International Life Sciences Fund III Co-Investment, L.P. ("ILSF Co-Invest") and (iii) International Life Sciences Fund III Strategic Partners, L.P. ("ILSF Strategic" and collectively, the "Fund III Entities"). ILSF III, LLC (the "ILSF General Partner") is the general partner of Fund III GP and, through an investment committee comprised of James Garvey, Kate Bingham, Eugene D. Hill, III and Michael Ross controls voting and investment decisions over the Issuer's shares held by the Fund III Entities by majority vote. F3: Each member of the investment committee of ILSF General Partner disclaims beneficial ownership over the Shares held by the Fund III Entities except to the extent of any pecuniary interest therein. Each of ILSF General Partner and Fund III GP disclaim beneficial ownership over the Shares held by the Fund III Entities except to the extent of their respective pecuniary interest therein. |
| Common Stock, $0.001 par valueSEC Table I · non-derivative | IndirectBy ILSF Strategic | 10,424 |
Reported balance
After 2017-01-31 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2017-01-31 · Sale · Disposed 2,106 · Balance 10,424 F1: Represents a public offering price of $17.00 per share before underwriting discounts and commissions pursuant to an Underwriting Agreement dated January 25, 2017, which offering closed on January 31, 2017. F2: International Life Sciences Fund III (GP), L.P. ("Fund III GP") is the general partner of each of: (i) International Life Sciences Fund III (LP1), L.P. ("ILSF LP1"), (ii) International Life Sciences Fund III Co-Investment, L.P. ("ILSF Co-Invest") and (iii) International Life Sciences Fund III Strategic Partners, L.P. ("ILSF Strategic" and collectively, the "Fund III Entities"). ILSF III, LLC (the "ILSF General Partner") is the general partner of Fund III GP and, through an investment committee comprised of James Garvey, Kate Bingham, Eugene D. Hill, III and Michael Ross controls voting and investment decisions over the Issuer's shares held by the Fund III Entities by majority vote. F3: Each member of the investment committee of ILSF General Partner disclaims beneficial ownership over the Shares held by the Fund III Entities except to the extent of any pecuniary interest therein. Each of ILSF General Partner and Fund III GP disclaim beneficial ownership over the Shares held by the Fund III Entities except to the extent of their respective pecuniary interest therein. |
| Common Stock, $0.001 par valueSEC Table I · non-derivative | IndirectBy Fund IV | 1,791,070 |
Reported balance
After 2017-01-31 transaction · row 4
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 4 · 2017-01-31 · Sale · Disposed 299,424 · Balance 1,791,070 F1: Represents a public offering price of $17.00 per share before underwriting discounts and commissions pursuant to an Underwriting Agreement dated January 25, 2017, which offering closed on January 31, 2017. F4: SV Life Sciences Fund IV (GP), L.P. ("Fund IV GP") is the general partner of each of SV Life Sciences Fund IV, L.P. ("Fund IV") and SV Life Sciences Fund IV Strategic Partners, L.P. ("Fund IV Strategic" and together with Fund IV, the "Fund IV Entities"). SVLSF IV, LLC (the "SVLS General Partner") is the general partner of Fund IV GP and, through an investment committee comprised of David Milne (also a member of the Issuer's board of directors), James Garvey, Kate Bingham, Eugene D. Hill, III and Michael Ross controls voting and investment decisions over the Issuer's shares held by the Fund IV Entities by a majority vote. F5: Each member of the investment committee of SVLS General Partner disclaims beneficial ownership over the Shares held by the Fund IV Entities except to the extent of any pecuniary interest therein. Each of SVLS General Partner and Fund IV GP disclaim beneficial ownership over the Shares held by the Fund IV Entities except to the extent of their respective pecuniary interest therein. |
| Common Stock, $0.001 par valueSEC Table I · non-derivative | IndirectBy Fund IV Strategic | 50,849 |
Reported balance
After 2017-01-31 transaction · row 5
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 5 · 2017-01-31 · Sale · Disposed 8,501 · Balance 50,849 F1: Represents a public offering price of $17.00 per share before underwriting discounts and commissions pursuant to an Underwriting Agreement dated January 25, 2017, which offering closed on January 31, 2017. F4: SV Life Sciences Fund IV (GP), L.P. ("Fund IV GP") is the general partner of each of SV Life Sciences Fund IV, L.P. ("Fund IV") and SV Life Sciences Fund IV Strategic Partners, L.P. ("Fund IV Strategic" and together with Fund IV, the "Fund IV Entities"). SVLSF IV, LLC (the "SVLS General Partner") is the general partner of Fund IV GP and, through an investment committee comprised of David Milne (also a member of the Issuer's board of directors), James Garvey, Kate Bingham, Eugene D. Hill, III and Michael Ross controls voting and investment decisions over the Issuer's shares held by the Fund IV Entities by a majority vote. F5: Each member of the investment committee of SVLS General Partner disclaims beneficial ownership over the Shares held by the Fund IV Entities except to the extent of any pecuniary interest therein. Each of SVLS General Partner and Fund IV GP disclaim beneficial ownership over the Shares held by the Fund IV Entities except to the extent of their respective pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a public offering price of $17.00 per share before underwriting discounts and commissions pursuant to an Underwriting Agreement dated January 25, 2017, which offering closed on January 31, 2017.
F2: International Life Sciences Fund III (GP), L.P. ("Fund III GP") is the general partner of each of: (i) International Life Sciences Fund III (LP1), L.P. ("ILSF LP1"), (ii) International Life Sciences Fund III Co-Investment, L.P. ("ILSF Co-Invest") and (iii) International Life Sciences Fund III Strategic Partners, L.P. ("ILSF Strategic" and collectively, the "Fund III Entities"). ILSF III, LLC (the "ILSF General Partner") is the general partner of Fund III GP and, through an investment committee comprised of James Garvey, Kate Bingham, Eugene D. Hill, III and Michael Ross controls voting and investment decisions over the Issuer's shares held by the Fund III Entities by majority vote.
F3: Each member of the investment committee of ILSF General Partner disclaims beneficial ownership over the Shares held by the Fund III Entities except to the extent of any pecuniary interest therein. Each of ILSF General Partner and Fund III GP disclaim beneficial ownership over the Shares held by the Fund III Entities except to the extent of their respective pecuniary interest therein.
F4: SV Life Sciences Fund IV (GP), L.P. ("Fund IV GP") is the general partner of each of SV Life Sciences Fund IV, L.P. ("Fund IV") and SV Life Sciences Fund IV Strategic Partners, L.P. ("Fund IV Strategic" and together with Fund IV, the "Fund IV Entities"). SVLSF IV, LLC (the "SVLS General Partner") is the general partner of Fund IV GP and, through an investment committee comprised of David Milne (also a member of the Issuer's board of directors), James Garvey, Kate Bingham, Eugene D. Hill, III and Michael Ross controls voting and investment decisions over the Issuer's shares held by the Fund IV Entities by a majority vote.
F5: Each member of the investment committee of SVLS General Partner disclaims beneficial ownership over the Shares held by the Fund IV Entities except to the extent of any pecuniary interest therein. Each of SVLS General Partner and Fund IV GP disclaim beneficial ownership over the Shares held by the Fund IV Entities except to the extent of their respective pecuniary interest therein.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
KalVista Pharmaceuticals, Inc.
Report date April 08, 2019 · Filed April 10, 2019
Jointly reported with SVLSF IV, LLC, SV Life Sciences Fund IV (GP), L.P., SV LIFE SCIENCES FUND IV STRATEGIC PARTNERS, L. P.
Section 16 reporting ended · disclosed 2019-04-10. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,698,554 |
Reported balance
After 2019-04-08 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2019-04-08 · Sale · Disposed 22,171 · Balance 1,698,554 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.13 to $30.08, inclusive. The Reporting Persons undertake to provide to the Registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2: These shares are held directly by SVLS IV LP. F3: SVLS IV LP and Strategic Partners (each a "Fund", or collectively the "Funds") may be deemed to beneficially own the shares held by each other Fund because of certain contractual relationships among the Funds and their affiliares. The Funds disclaim beneficial ownership of shares held by any other Fund except to the extent of any pecuniary interest therein. SVLS IV GP, the general partner of the Funds, may be deemed to share voting and dispositive power over the shares held by the Funds. SVLS IV GP disclaims beneficial ownership of shares held by the Funds, except to the extent of any pecuniary interest therein. SVLSF IV, LLC, the general partner of SVLS IV GP. may be deemed to share voting and dispositive power over the shares held by the Funds. SVLSF IV, LLC. disclaims beneficial ownership of shares held by the Funds except to the extent of any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | Direct | 48,222 |
Reported balance
After 2019-04-08 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2019-04-08 · Sale · Disposed 629 · Balance 48,222 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.13 to $30.08, inclusive. The Reporting Persons undertake to provide to the Registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3: SVLS IV LP and Strategic Partners (each a "Fund", or collectively the "Funds") may be deemed to beneficially own the shares held by each other Fund because of certain contractual relationships among the Funds and their affiliares. The Funds disclaim beneficial ownership of shares held by any other Fund except to the extent of any pecuniary interest therein. SVLS IV GP, the general partner of the Funds, may be deemed to share voting and dispositive power over the shares held by the Funds. SVLS IV GP disclaims beneficial ownership of shares held by the Funds, except to the extent of any pecuniary interest therein. SVLSF IV, LLC, the general partner of SVLS IV GP. may be deemed to share voting and dispositive power over the shares held by the Funds. SVLSF IV, LLC. disclaims beneficial ownership of shares held by the Funds except to the extent of any pecuniary interest therein. F4: These shares are held directly by Strategic Partners. |
| Common StockSEC Table I · non-derivative | Direct | 1,685,262 |
Reported balance
After 2019-04-09 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2019-04-09 · Sale · Disposed 13,292 · Balance 1,685,262 F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.02 to $29.685, inclusive. The Reporting Persons undertake to provide to Registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2: These shares are held directly by SVLS IV LP. F3: SVLS IV LP and Strategic Partners (each a "Fund", or collectively the "Funds") may be deemed to beneficially own the shares held by each other Fund because of certain contractual relationships among the Funds and their affiliares. The Funds disclaim beneficial ownership of shares held by any other Fund except to the extent of any pecuniary interest therein. SVLS IV GP, the general partner of the Funds, may be deemed to share voting and dispositive power over the shares held by the Funds. SVLS IV GP disclaims beneficial ownership of shares held by the Funds, except to the extent of any pecuniary interest therein. SVLSF IV, LLC, the general partner of SVLS IV GP. may be deemed to share voting and dispositive power over the shares held by the Funds. SVLSF IV, LLC. disclaims beneficial ownership of shares held by the Funds except to the extent of any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | Direct | 47,845 |
Reported balance
After 2019-04-09 transaction · row 4
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 4 · 2019-04-09 · Sale · Disposed 377 · Balance 47,845 F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.02 to $29.685, inclusive. The Reporting Persons undertake to provide to Registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3: SVLS IV LP and Strategic Partners (each a "Fund", or collectively the "Funds") may be deemed to beneficially own the shares held by each other Fund because of certain contractual relationships among the Funds and their affiliares. The Funds disclaim beneficial ownership of shares held by any other Fund except to the extent of any pecuniary interest therein. SVLS IV GP, the general partner of the Funds, may be deemed to share voting and dispositive power over the shares held by the Funds. SVLS IV GP disclaims beneficial ownership of shares held by the Funds, except to the extent of any pecuniary interest therein. SVLSF IV, LLC, the general partner of SVLS IV GP. may be deemed to share voting and dispositive power over the shares held by the Funds. SVLSF IV, LLC. disclaims beneficial ownership of shares held by the Funds except to the extent of any pecuniary interest therein. F4: These shares are held directly by Strategic Partners. |
| Common StockSEC Table I · non-derivative | Direct | 1,672,105 |
Reported balance
After 2019-04-10 transaction · row 5
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 5 · 2019-04-10 · Sale · Disposed 13,157 · Balance 1,672,105 F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.07 to $29.71, inclusive. The Reporting Persons undertake to provide to Registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2: These shares are held directly by SVLS IV LP. F3: SVLS IV LP and Strategic Partners (each a "Fund", or collectively the "Funds") may be deemed to beneficially own the shares held by each other Fund because of certain contractual relationships among the Funds and their affiliares. The Funds disclaim beneficial ownership of shares held by any other Fund except to the extent of any pecuniary interest therein. SVLS IV GP, the general partner of the Funds, may be deemed to share voting and dispositive power over the shares held by the Funds. SVLS IV GP disclaims beneficial ownership of shares held by the Funds, except to the extent of any pecuniary interest therein. SVLSF IV, LLC, the general partner of SVLS IV GP. may be deemed to share voting and dispositive power over the shares held by the Funds. SVLSF IV, LLC. disclaims beneficial ownership of shares held by the Funds except to the extent of any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | Direct | 47,471 |
Reported balance
After 2019-04-10 transaction · row 6
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 6 · 2019-04-10 · Sale · Disposed 374 · Balance 47,471 F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.07 to $29.71, inclusive. The Reporting Persons undertake to provide to Registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3: SVLS IV LP and Strategic Partners (each a "Fund", or collectively the "Funds") may be deemed to beneficially own the shares held by each other Fund because of certain contractual relationships among the Funds and their affiliares. The Funds disclaim beneficial ownership of shares held by any other Fund except to the extent of any pecuniary interest therein. SVLS IV GP, the general partner of the Funds, may be deemed to share voting and dispositive power over the shares held by the Funds. SVLS IV GP disclaims beneficial ownership of shares held by the Funds, except to the extent of any pecuniary interest therein. SVLSF IV, LLC, the general partner of SVLS IV GP. may be deemed to share voting and dispositive power over the shares held by the Funds. SVLSF IV, LLC. disclaims beneficial ownership of shares held by the Funds except to the extent of any pecuniary interest therein. F4: These shares are held directly by Strategic Partners. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.13 to $30.08, inclusive. The Reporting Persons undertake to provide to the Registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2: These shares are held directly by SVLS IV LP.
F3: SVLS IV LP and Strategic Partners (each a "Fund", or collectively the "Funds") may be deemed to beneficially own the shares held by each other Fund because of certain contractual relationships among the Funds and their affiliares. The Funds disclaim beneficial ownership of shares held by any other Fund except to the extent of any pecuniary interest therein. SVLS IV GP, the general partner of the Funds, may be deemed to share voting and dispositive power over the shares held by the Funds. SVLS IV GP disclaims beneficial ownership of shares held by the Funds, except to the extent of any pecuniary interest therein. SVLSF IV, LLC, the general partner of SVLS IV GP. may be deemed to share voting and dispositive power over the shares held by the Funds. SVLSF IV, LLC. disclaims beneficial ownership of shares held by the Funds except to the extent of any pecuniary interest therein.
F4: These shares are held directly by Strategic Partners.
F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.02 to $29.685, inclusive. The Reporting Persons undertake to provide to Registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.07 to $29.71, inclusive. The Reporting Persons undertake to provide to Registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 10, 2019 Filed Apr 10, 2019 19:21 UTC | KalVista Pharmaceuticals, Inc. KALV · Entity 39180 | SaleCommon Stock | 374 | $29.40 | $10,993.80 |
DisclosureSEC source: 0000899243-19-010492 · doc4.xml · nonDerivative · entry 6 SVLSF IV, LLC · CIK 0001422339 · 10% owner SV Life Sciences Fund IV (GP), L.P. · CIK 0001422340 · 10% owner SV LIFE SCIENCES FUND IV STRATEGIC PARTNERS, L. P. · CIK 0001392309 · 10% owner SV LIFE SCIENCES FUND IV, L.P. · CIK 0001367381 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,471 F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.07 to $29.71, inclusive. The Reporting Persons undertake to provide to Registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.direct: SVLS IV LP and Strategic Partners (each a "Fund", or collectively the "Funds") may be deemed to beneficially own the shares held by each other Fund because of certain contractual relationships among the Funds and their affiliares. The Funds disclaim beneficial ownership of shares held by any other Fund except to the extent of any pecuniary interest therein. SVLS IV GP, the general partner of the Funds, may be deemed to share voting and dispositive power over the shares held by the Funds. SVLS IV GP disclaims beneficial ownership of shares held by the Funds, except to the extent of any pecuniary interest therein. SVLSF IV, LLC, the general partner of SVLS IV GP. may be deemed to share voting and dispositive power over the shares held by the Funds. SVLSF IV, LLC. disclaims beneficial ownership of shares held by the Funds except to the extent of any pecuniary interest therein. F4 · ownership.direct: These shares are held directly by Strategic Partners. Read SEC document |
| April 10, 2019 Filed Apr 10, 2019 19:21 UTC | KalVista Pharmaceuticals, Inc. KALV · Entity 39180 | SaleCommon Stock | 13,157 | $29.40 | $386,752.65 |
DisclosureSEC source: 0000899243-19-010492 · doc4.xml · nonDerivative · entry 5 SVLSF IV, LLC · CIK 0001422339 · 10% owner SV Life Sciences Fund IV (GP), L.P. · CIK 0001422340 · 10% owner SV LIFE SCIENCES FUND IV STRATEGIC PARTNERS, L. P. · CIK 0001392309 · 10% owner SV LIFE SCIENCES FUND IV, L.P. · CIK 0001367381 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,672,105 F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.07 to $29.71, inclusive. The Reporting Persons undertake to provide to Registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.direct: These shares are held directly by SVLS IV LP. F3 · ownership.direct: SVLS IV LP and Strategic Partners (each a "Fund", or collectively the "Funds") may be deemed to beneficially own the shares held by each other Fund because of certain contractual relationships among the Funds and their affiliares. The Funds disclaim beneficial ownership of shares held by any other Fund except to the extent of any pecuniary interest therein. SVLS IV GP, the general partner of the Funds, may be deemed to share voting and dispositive power over the shares held by the Funds. SVLS IV GP disclaims beneficial ownership of shares held by the Funds, except to the extent of any pecuniary interest therein. SVLSF IV, LLC, the general partner of SVLS IV GP. may be deemed to share voting and dispositive power over the shares held by the Funds. SVLSF IV, LLC. disclaims beneficial ownership of shares held by the Funds except to the extent of any pecuniary interest therein. Read SEC document |
| April 09, 2019 Filed Apr 10, 2019 19:21 UTC | KalVista Pharmaceuticals, Inc. KALV · Entity 39180 | SaleCommon Stock | 377 | $28.53 | $10,756.00 |
DisclosureSEC source: 0000899243-19-010492 · doc4.xml · nonDerivative · entry 4 SVLSF IV, LLC · CIK 0001422339 · 10% owner SV Life Sciences Fund IV (GP), L.P. · CIK 0001422340 · 10% owner SV LIFE SCIENCES FUND IV STRATEGIC PARTNERS, L. P. · CIK 0001392309 · 10% owner SV LIFE SCIENCES FUND IV, L.P. · CIK 0001367381 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,845 F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.02 to $29.685, inclusive. The Reporting Persons undertake to provide to Registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.direct: SVLS IV LP and Strategic Partners (each a "Fund", or collectively the "Funds") may be deemed to beneficially own the shares held by each other Fund because of certain contractual relationships among the Funds and their affiliares. The Funds disclaim beneficial ownership of shares held by any other Fund except to the extent of any pecuniary interest therein. SVLS IV GP, the general partner of the Funds, may be deemed to share voting and dispositive power over the shares held by the Funds. SVLS IV GP disclaims beneficial ownership of shares held by the Funds, except to the extent of any pecuniary interest therein. SVLSF IV, LLC, the general partner of SVLS IV GP. may be deemed to share voting and dispositive power over the shares held by the Funds. SVLSF IV, LLC. disclaims beneficial ownership of shares held by the Funds except to the extent of any pecuniary interest therein. F4 · ownership.direct: These shares are held directly by Strategic Partners. Read SEC document |
| April 09, 2019 Filed Apr 10, 2019 19:21 UTC | KalVista Pharmaceuticals, Inc. KALV · Entity 39180 | SaleCommon Stock | 13,292 | $28.53 | $379,227.41 |
DisclosureSEC source: 0000899243-19-010492 · doc4.xml · nonDerivative · entry 3 SVLSF IV, LLC · CIK 0001422339 · 10% owner SV Life Sciences Fund IV (GP), L.P. · CIK 0001422340 · 10% owner SV LIFE SCIENCES FUND IV STRATEGIC PARTNERS, L. P. · CIK 0001392309 · 10% owner SV LIFE SCIENCES FUND IV, L.P. · CIK 0001367381 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,685,262 F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.02 to $29.685, inclusive. The Reporting Persons undertake to provide to Registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.direct: These shares are held directly by SVLS IV LP. F3 · ownership.direct: SVLS IV LP and Strategic Partners (each a "Fund", or collectively the "Funds") may be deemed to beneficially own the shares held by each other Fund because of certain contractual relationships among the Funds and their affiliares. The Funds disclaim beneficial ownership of shares held by any other Fund except to the extent of any pecuniary interest therein. SVLS IV GP, the general partner of the Funds, may be deemed to share voting and dispositive power over the shares held by the Funds. SVLS IV GP disclaims beneficial ownership of shares held by the Funds, except to the extent of any pecuniary interest therein. SVLSF IV, LLC, the general partner of SVLS IV GP. may be deemed to share voting and dispositive power over the shares held by the Funds. SVLSF IV, LLC. disclaims beneficial ownership of shares held by the Funds except to the extent of any pecuniary interest therein. Read SEC document |
| April 08, 2019 Filed Apr 10, 2019 19:21 UTC | KalVista Pharmaceuticals, Inc. KALV · Entity 39180 | SaleCommon Stock | 629 | $29.49 | $18,550.41 |
DisclosureSEC source: 0000899243-19-010492 · doc4.xml · nonDerivative · entry 2 SVLSF IV, LLC · CIK 0001422339 · 10% owner SV Life Sciences Fund IV (GP), L.P. · CIK 0001422340 · 10% owner SV LIFE SCIENCES FUND IV STRATEGIC PARTNERS, L. P. · CIK 0001392309 · 10% owner SV LIFE SCIENCES FUND IV, L.P. · CIK 0001367381 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,222 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.13 to $30.08, inclusive. The Reporting Persons undertake to provide to the Registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.direct: SVLS IV LP and Strategic Partners (each a "Fund", or collectively the "Funds") may be deemed to beneficially own the shares held by each other Fund because of certain contractual relationships among the Funds and their affiliares. The Funds disclaim beneficial ownership of shares held by any other Fund except to the extent of any pecuniary interest therein. SVLS IV GP, the general partner of the Funds, may be deemed to share voting and dispositive power over the shares held by the Funds. SVLS IV GP disclaims beneficial ownership of shares held by the Funds, except to the extent of any pecuniary interest therein. SVLSF IV, LLC, the general partner of SVLS IV GP. may be deemed to share voting and dispositive power over the shares held by the Funds. SVLSF IV, LLC. disclaims beneficial ownership of shares held by the Funds except to the extent of any pecuniary interest therein. F4 · ownership.direct: These shares are held directly by Strategic Partners. Read SEC document |
| April 08, 2019 Filed Apr 10, 2019 19:21 UTC | KalVista Pharmaceuticals, Inc. KALV · Entity 39180 | SaleCommon Stock | 22,171 | $29.49 | $653,864.91 |
DisclosureSEC source: 0000899243-19-010492 · doc4.xml · nonDerivative · entry 1 SVLSF IV, LLC · CIK 0001422339 · 10% owner SV Life Sciences Fund IV (GP), L.P. · CIK 0001422340 · 10% owner SV LIFE SCIENCES FUND IV STRATEGIC PARTNERS, L. P. · CIK 0001392309 · 10% owner SV LIFE SCIENCES FUND IV, L.P. · CIK 0001367381 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,698,554 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.13 to $30.08, inclusive. The Reporting Persons undertake to provide to the Registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.direct: These shares are held directly by SVLS IV LP. F3 · ownership.direct: SVLS IV LP and Strategic Partners (each a "Fund", or collectively the "Funds") may be deemed to beneficially own the shares held by each other Fund because of certain contractual relationships among the Funds and their affiliares. The Funds disclaim beneficial ownership of shares held by any other Fund except to the extent of any pecuniary interest therein. SVLS IV GP, the general partner of the Funds, may be deemed to share voting and dispositive power over the shares held by the Funds. SVLS IV GP disclaims beneficial ownership of shares held by the Funds, except to the extent of any pecuniary interest therein. SVLSF IV, LLC, the general partner of SVLS IV GP. may be deemed to share voting and dispositive power over the shares held by the Funds. SVLSF IV, LLC. disclaims beneficial ownership of shares held by the Funds except to the extent of any pecuniary interest therein. Read SEC document |
| April 02, 2019 Filed Apr 2, 2019 18:57 UTC | KalVista Pharmaceuticals, Inc. KALV · Entity 39180 | SaleCommon Stock | 253 | $28.76 | $7,277.24 |
DisclosureSEC source: 0000899243-19-009640 · doc4.xml · nonDerivative · entry 6 SVLSF IV, LLC · CIK 0001422339 · 10% owner SV Life Sciences Fund IV (GP), L.P. · CIK 0001422340 · 10% owner SV LIFE SCIENCES FUND IV STRATEGIC PARTNERS, L. P. · CIK 0001392309 · 10% owner SV LIFE SCIENCES FUND IV, L.P. · CIK 0001367381 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,851 F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.53 to $29.14, inclusive. The Reporting Persons undertake to provide to Registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.direct: SVLS IV LP and Strategic Partners (each a "Fund", or collectively the "Funds") may be deemed to beneficially own the shares held by each other Fund because of certain contractual relationships among the Funds and their affiliares. The Funds disclaim beneficial ownership of shares held by any other Fund except to the extent of any pecuniary interest therein. SVLS IV GP, the general partner of the Funds, may be deemed to share voting and dispositive power over the shares held by the Funds. SVLS IV GP disclaims beneficial ownership of shares held by the Funds, except to the extent of any pecuniary interest therein. SVLSF IV, LLC, the general partner of SVLS IV GP. may be deemed to share voting and dispositive power over the shares held by the Funds. SVLSF IV, LLC. disclaims beneficial ownership of shares held by the Funds except to the extent of any pecuniary interest therein. F4 · ownership.direct: These shares are held directly by Strategic Partners. Read SEC document |
| April 02, 2019 Filed Apr 2, 2019 18:57 UTC | KalVista Pharmaceuticals, Inc. KALV · Entity 39180 | SaleCommon Stock | 8,888 | $28.76 | $255,652.65 |
DisclosureSEC source: 0000899243-19-009640 · doc4.xml · nonDerivative · entry 5 SVLSF IV, LLC · CIK 0001422339 · 10% owner SV Life Sciences Fund IV (GP), L.P. · CIK 0001422340 · 10% owner SV LIFE SCIENCES FUND IV STRATEGIC PARTNERS, L. P. · CIK 0001392309 · 10% owner SV LIFE SCIENCES FUND IV, L.P. · CIK 0001367381 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,720,725 F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.53 to $29.14, inclusive. The Reporting Persons undertake to provide to Registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.direct: These shares are held directly by SVLS IV LP. F3 · ownership.direct: SVLS IV LP and Strategic Partners (each a "Fund", or collectively the "Funds") may be deemed to beneficially own the shares held by each other Fund because of certain contractual relationships among the Funds and their affiliares. The Funds disclaim beneficial ownership of shares held by any other Fund except to the extent of any pecuniary interest therein. SVLS IV GP, the general partner of the Funds, may be deemed to share voting and dispositive power over the shares held by the Funds. SVLS IV GP disclaims beneficial ownership of shares held by the Funds, except to the extent of any pecuniary interest therein. SVLSF IV, LLC, the general partner of SVLS IV GP. may be deemed to share voting and dispositive power over the shares held by the Funds. SVLSF IV, LLC. disclaims beneficial ownership of shares held by the Funds except to the extent of any pecuniary interest therein. Read SEC document |
| April 01, 2019 Filed Apr 2, 2019 18:57 UTC | KalVista Pharmaceuticals, Inc. KALV · Entity 39180 | SaleCommon Stock | 1,458 | $27.66 | $40,325.66 |
DisclosureSEC source: 0000899243-19-009640 · doc4.xml · nonDerivative · entry 4 SVLSF IV, LLC · CIK 0001422339 · 10% owner SV Life Sciences Fund IV (GP), L.P. · CIK 0001422340 · 10% owner SV LIFE SCIENCES FUND IV STRATEGIC PARTNERS, L. P. · CIK 0001392309 · 10% owner SV LIFE SCIENCES FUND IV, L.P. · CIK 0001367381 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,104 F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.84 to $28.78, inclusive. The Reporting Persons undertake to provide to Registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.direct: SVLS IV LP and Strategic Partners (each a "Fund", or collectively the "Funds") may be deemed to beneficially own the shares held by each other Fund because of certain contractual relationships among the Funds and their affiliares. The Funds disclaim beneficial ownership of shares held by any other Fund except to the extent of any pecuniary interest therein. SVLS IV GP, the general partner of the Funds, may be deemed to share voting and dispositive power over the shares held by the Funds. SVLS IV GP disclaims beneficial ownership of shares held by the Funds, except to the extent of any pecuniary interest therein. SVLSF IV, LLC, the general partner of SVLS IV GP. may be deemed to share voting and dispositive power over the shares held by the Funds. SVLSF IV, LLC. disclaims beneficial ownership of shares held by the Funds except to the extent of any pecuniary interest therein. F4 · ownership.direct: These shares are held directly by Strategic Partners. Read SEC document |
| April 01, 2019 Filed Apr 2, 2019 18:57 UTC | KalVista Pharmaceuticals, Inc. KALV · Entity 39180 | SaleCommon Stock | 51,373 | $27.66 | $1,420,884.71 |
DisclosureSEC source: 0000899243-19-009640 · doc4.xml · nonDerivative · entry 3 SVLSF IV, LLC · CIK 0001422339 · 10% owner SV Life Sciences Fund IV (GP), L.P. · CIK 0001422340 · 10% owner SV LIFE SCIENCES FUND IV STRATEGIC PARTNERS, L. P. · CIK 0001392309 · 10% owner SV LIFE SCIENCES FUND IV, L.P. · CIK 0001367381 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,729,613 F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.84 to $28.78, inclusive. The Reporting Persons undertake to provide to Registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.direct: These shares are held directly by SVLS IV LP. F3 · ownership.direct: SVLS IV LP and Strategic Partners (each a "Fund", or collectively the "Funds") may be deemed to beneficially own the shares held by each other Fund because of certain contractual relationships among the Funds and their affiliares. The Funds disclaim beneficial ownership of shares held by any other Fund except to the extent of any pecuniary interest therein. SVLS IV GP, the general partner of the Funds, may be deemed to share voting and dispositive power over the shares held by the Funds. SVLS IV GP disclaims beneficial ownership of shares held by the Funds, except to the extent of any pecuniary interest therein. SVLSF IV, LLC, the general partner of SVLS IV GP. may be deemed to share voting and dispositive power over the shares held by the Funds. SVLSF IV, LLC. disclaims beneficial ownership of shares held by the Funds except to the extent of any pecuniary interest therein. Read SEC document |
| March 29, 2019 Filed Apr 2, 2019 18:57 UTC | KalVista Pharmaceuticals, Inc. KALV · Entity 39180 | SaleCommon Stock | 969 | $28.40 | $27,515.72 |
DisclosureSEC source: 0000899243-19-009640 · doc4.xml · nonDerivative · entry 2 SVLSF IV, LLC · CIK 0001422339 · 10% owner SV Life Sciences Fund IV (GP), L.P. · CIK 0001422340 · 10% owner SV LIFE SCIENCES FUND IV STRATEGIC PARTNERS, L. P. · CIK 0001392309 · 10% owner SV LIFE SCIENCES FUND IV, L.P. · CIK 0001367381 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,562 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.62 to $29.13, inclusive. The Reporting Persons undertake to provide to the Registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.direct: SVLS IV LP and Strategic Partners (each a "Fund", or collectively the "Funds") may be deemed to beneficially own the shares held by each other Fund because of certain contractual relationships among the Funds and their affiliares. The Funds disclaim beneficial ownership of shares held by any other Fund except to the extent of any pecuniary interest therein. SVLS IV GP, the general partner of the Funds, may be deemed to share voting and dispositive power over the shares held by the Funds. SVLS IV GP disclaims beneficial ownership of shares held by the Funds, except to the extent of any pecuniary interest therein. SVLSF IV, LLC, the general partner of SVLS IV GP. may be deemed to share voting and dispositive power over the shares held by the Funds. SVLSF IV, LLC. disclaims beneficial ownership of shares held by the Funds except to the extent of any pecuniary interest therein. F4 · ownership.direct: These shares are held directly by Strategic Partners. Read SEC document |
| March 29, 2019 Filed Apr 2, 2019 18:57 UTC | KalVista Pharmaceuticals, Inc. KALV · Entity 39180 | SaleCommon Stock | 34,133 | $28.40 | $969,240.67 |
DisclosureSEC source: 0000899243-19-009640 · doc4.xml · nonDerivative · entry 1 SVLSF IV, LLC · CIK 0001422339 · 10% owner SV Life Sciences Fund IV (GP), L.P. · CIK 0001422340 · 10% owner SV LIFE SCIENCES FUND IV STRATEGIC PARTNERS, L. P. · CIK 0001392309 · 10% owner SV LIFE SCIENCES FUND IV, L.P. · CIK 0001367381 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,780,986 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.62 to $29.13, inclusive. The Reporting Persons undertake to provide to the Registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.direct: These shares are held directly by SVLS IV LP. F3 · ownership.direct: SVLS IV LP and Strategic Partners (each a "Fund", or collectively the "Funds") may be deemed to beneficially own the shares held by each other Fund because of certain contractual relationships among the Funds and their affiliares. The Funds disclaim beneficial ownership of shares held by any other Fund except to the extent of any pecuniary interest therein. SVLS IV GP, the general partner of the Funds, may be deemed to share voting and dispositive power over the shares held by the Funds. SVLS IV GP disclaims beneficial ownership of shares held by the Funds, except to the extent of any pecuniary interest therein. SVLSF IV, LLC, the general partner of SVLS IV GP. may be deemed to share voting and dispositive power over the shares held by the Funds. SVLSF IV, LLC. disclaims beneficial ownership of shares held by the Funds except to the extent of any pecuniary interest therein. Read SEC document |
| March 28, 2019 Filed Mar 28, 2019 17:29 UTC | KalVista Pharmaceuticals, Inc. KALV · Entity 39180 | SaleCommon Stock | 1,012 | $27.80 | $28,134.61 |
DisclosureSEC source: 0000899243-19-009178 · doc4.xml · nonDerivative · entry 6 SVLSF IV, LLC · CIK 0001422339 · 10% owner SV Life Sciences Fund IV (GP), L.P. · CIK 0001422340 · 10% owner SV LIFE SCIENCES FUND IV STRATEGIC PARTNERS, L. P. · CIK 0001392309 · 10% owner SV LIFE SCIENCES FUND IV, L.P. · CIK 0001367381 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,531 F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.26 to $29.10, inclusive. The Reporting Persons undertake to provide to Registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.direct: SVLS IV LP and Strategic Partners (each a "Fund", or collectively the "Funds") may be deemed to beneficially own the shares held by each other Fund because of certain contractual relationships among the Funds and their affiliares. The Funds disclaim beneficial ownership of shares held by any other Fund except to the extent of any pecuniary interest therein. SVLS IV GP, the general partner of the Funds, may be deemed to share voting and dispositive power over the shares held by the Funds. SVLS IV GP disclaims beneficial ownership of shares held by the Funds, except to the extent of any pecuniary interest therein. SVLSF IV, LLC, the general partner of SVLS IV GP. may be deemed to share voting and dispositive power over the shares held by the Funds. SVLSF IV, LLC. disclaims beneficial ownership of shares held by the Funds except to the extent of any pecuniary interest therein. F4 · ownership.direct: These shares are held directly by Strategic Partners. Read SEC document |
| March 28, 2019 Filed Mar 28, 2019 17:29 UTC | KalVista Pharmaceuticals, Inc. KALV · Entity 39180 | SaleCommon Stock | 35,653 | $27.80 | $991,189.05 |
DisclosureSEC source: 0000899243-19-009178 · doc4.xml · nonDerivative · entry 5 SVLSF IV, LLC · CIK 0001422339 · 10% owner SV Life Sciences Fund IV (GP), L.P. · CIK 0001422340 · 10% owner SV LIFE SCIENCES FUND IV STRATEGIC PARTNERS, L. P. · CIK 0001392309 · 10% owner SV LIFE SCIENCES FUND IV, L.P. · CIK 0001367381 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,815,119 F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.26 to $29.10, inclusive. The Reporting Persons undertake to provide to Registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.direct: These shares are held directly by SVLS IV LP. F3 · ownership.direct: SVLS IV LP and Strategic Partners (each a "Fund", or collectively the "Funds") may be deemed to beneficially own the shares held by each other Fund because of certain contractual relationships among the Funds and their affiliares. The Funds disclaim beneficial ownership of shares held by any other Fund except to the extent of any pecuniary interest therein. SVLS IV GP, the general partner of the Funds, may be deemed to share voting and dispositive power over the shares held by the Funds. SVLS IV GP disclaims beneficial ownership of shares held by the Funds, except to the extent of any pecuniary interest therein. SVLSF IV, LLC, the general partner of SVLS IV GP. may be deemed to share voting and dispositive power over the shares held by the Funds. SVLSF IV, LLC. disclaims beneficial ownership of shares held by the Funds except to the extent of any pecuniary interest therein. Read SEC document |
| March 27, 2019 Filed Mar 28, 2019 17:29 UTC | KalVista Pharmaceuticals, Inc. KALV · Entity 39180 | SaleCommon Stock | 1,599 | $29.06 | $46,465.66 |
DisclosureSEC source: 0000899243-19-009178 · doc4.xml · nonDerivative · entry 4 SVLSF IV, LLC · CIK 0001422339 · 10% owner SV Life Sciences Fund IV (GP), L.P. · CIK 0001422340 · 10% owner SV LIFE SCIENCES FUND IV STRATEGIC PARTNERS, L. P. · CIK 0001392309 · 10% owner SV LIFE SCIENCES FUND IV, L.P. · CIK 0001367381 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,543 F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.14 to $30.425, inclusive. The Reporting Persons undertake to provide to Registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.direct: SVLS IV LP and Strategic Partners (each a "Fund", or collectively the "Funds") may be deemed to beneficially own the shares held by each other Fund because of certain contractual relationships among the Funds and their affiliares. The Funds disclaim beneficial ownership of shares held by any other Fund except to the extent of any pecuniary interest therein. SVLS IV GP, the general partner of the Funds, may be deemed to share voting and dispositive power over the shares held by the Funds. SVLS IV GP disclaims beneficial ownership of shares held by the Funds, except to the extent of any pecuniary interest therein. SVLSF IV, LLC, the general partner of SVLS IV GP. may be deemed to share voting and dispositive power over the shares held by the Funds. SVLSF IV, LLC. disclaims beneficial ownership of shares held by the Funds except to the extent of any pecuniary interest therein. F4 · ownership.direct: These shares are held directly by Strategic Partners. Read SEC document |
| March 27, 2019 Filed Mar 28, 2019 17:29 UTC | KalVista Pharmaceuticals, Inc. KALV · Entity 39180 | SaleCommon Stock | 56,318 | $29.06 | $1,636,556.03 |
DisclosureSEC source: 0000899243-19-009178 · doc4.xml · nonDerivative · entry 3 SVLSF IV, LLC · CIK 0001422339 · 10% owner SV Life Sciences Fund IV (GP), L.P. · CIK 0001422340 · 10% owner SV LIFE SCIENCES FUND IV STRATEGIC PARTNERS, L. P. · CIK 0001392309 · 10% owner SV LIFE SCIENCES FUND IV, L.P. · CIK 0001367381 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,850,772 F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.14 to $30.425, inclusive. The Reporting Persons undertake to provide to Registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.direct: These shares are held directly by SVLS IV LP. F3 · ownership.direct: SVLS IV LP and Strategic Partners (each a "Fund", or collectively the "Funds") may be deemed to beneficially own the shares held by each other Fund because of certain contractual relationships among the Funds and their affiliares. The Funds disclaim beneficial ownership of shares held by any other Fund except to the extent of any pecuniary interest therein. SVLS IV GP, the general partner of the Funds, may be deemed to share voting and dispositive power over the shares held by the Funds. SVLS IV GP disclaims beneficial ownership of shares held by the Funds, except to the extent of any pecuniary interest therein. SVLSF IV, LLC, the general partner of SVLS IV GP. may be deemed to share voting and dispositive power over the shares held by the Funds. SVLSF IV, LLC. disclaims beneficial ownership of shares held by the Funds except to the extent of any pecuniary interest therein. Read SEC document |
| March 26, 2019 Filed Mar 28, 2019 17:29 UTC | KalVista Pharmaceuticals, Inc. KALV · Entity 39180 | SaleCommon Stock | 831 | $29.70 | $24,678.62 |
DisclosureSEC source: 0000899243-19-009178 · doc4.xml · nonDerivative · entry 2 SVLSF IV, LLC · CIK 0001422339 · 10% owner SV Life Sciences Fund IV (GP), L.P. · CIK 0001422340 · 10% owner SV LIFE SCIENCES FUND IV STRATEGIC PARTNERS, L. P. · CIK 0001392309 · 10% owner SV LIFE SCIENCES FUND IV, L.P. · CIK 0001367381 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,142 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.68 to $30.01, inclusive. The Reporting Persons undertake to provide to the Registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.direct: SVLS IV LP and Strategic Partners (each a "Fund", or collectively the "Funds") may be deemed to beneficially own the shares held by each other Fund because of certain contractual relationships among the Funds and their affiliares. The Funds disclaim beneficial ownership of shares held by any other Fund except to the extent of any pecuniary interest therein. SVLS IV GP, the general partner of the Funds, may be deemed to share voting and dispositive power over the shares held by the Funds. SVLS IV GP disclaims beneficial ownership of shares held by the Funds, except to the extent of any pecuniary interest therein. SVLSF IV, LLC, the general partner of SVLS IV GP. may be deemed to share voting and dispositive power over the shares held by the Funds. SVLSF IV, LLC. disclaims beneficial ownership of shares held by the Funds except to the extent of any pecuniary interest therein. F4 · ownership.direct: These shares are held directly by Strategic Partners. Read SEC document |
| March 26, 2019 Filed Mar 28, 2019 17:29 UTC | KalVista Pharmaceuticals, Inc. KALV · Entity 39180 | SaleCommon Stock | 29,262 | $29.70 | $869,008.25 |
DisclosureSEC source: 0000899243-19-009178 · doc4.xml · nonDerivative · entry 1 SVLSF IV, LLC · CIK 0001422339 · 10% owner SV Life Sciences Fund IV (GP), L.P. · CIK 0001422340 · 10% owner SV LIFE SCIENCES FUND IV STRATEGIC PARTNERS, L. P. · CIK 0001392309 · 10% owner SV LIFE SCIENCES FUND IV, L.P. · CIK 0001367381 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,907,090 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.68 to $30.01, inclusive. The Reporting Persons undertake to provide to the Registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.direct: These shares are held directly by SVLS IV LP. F3 · ownership.direct: SVLS IV LP and Strategic Partners (each a "Fund", or collectively the "Funds") may be deemed to beneficially own the shares held by each other Fund because of certain contractual relationships among the Funds and their affiliares. The Funds disclaim beneficial ownership of shares held by any other Fund except to the extent of any pecuniary interest therein. SVLS IV GP, the general partner of the Funds, may be deemed to share voting and dispositive power over the shares held by the Funds. SVLS IV GP disclaims beneficial ownership of shares held by the Funds, except to the extent of any pecuniary interest therein. SVLSF IV, LLC, the general partner of SVLS IV GP. may be deemed to share voting and dispositive power over the shares held by the Funds. SVLSF IV, LLC. disclaims beneficial ownership of shares held by the Funds except to the extent of any pecuniary interest therein. Read SEC document |
| March 18, 2019 Filed Mar 20, 2019 16:13 UTC | KalVista Pharmaceuticals, Inc. KALV · Entity 39180 | SaleCommon Stock | 7,246 | $26.70 | $193,468.20 |
DisclosureSEC source: 0000899243-19-008526 · doc4.xml · nonDerivative · entry 2 SVLSF IV, LLC · CIK 0001422339 · 10% owner SV Life Sciences Fund IV (GP), L.P. · CIK 0001422340 · 10% owner SV LIFE SCIENCES FUND IV STRATEGIC PARTNERS, L. P. · CIK 0001392309 · 10% owner SV LIFE SCIENCES FUND IV, L.P. · CIK 0001367381 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,973 F2 · ownership.direct: SVLS IV LP and Strategic Partners (each a "Fund", or collectively the "Funds") may be deemed to beneficially own the shares held by each other Fund because of certain contractual relationships among the Funds and their affiliares. The Funds disclaim beneficial ownership of shares held by any other Fund except to the extent of any pecuniary interest therein. SVLS IV GP, the general partner of the Funds, may be deemed to share voting and dispositive power over the shares held by the Funds. SVLS IV GP disclaims beneficial ownership of shares held by the Funds, except to the extent of any pecuniary interest therein. SVLSF IV, LLC, the general partner of SVLS IV GP. may be deemed to share voting and dispositive power over the shares held by the Funds. SVLSF IV, LLC. disclaims beneficial ownership of shares held by the Funds except to the extent of any pecuniary interest therein. F3 · ownership.direct: These shares are held directly by Strategic Partners. Read SEC document |
| March 18, 2019 Filed Mar 20, 2019 16:13 UTC | KalVista Pharmaceuticals, Inc. KALV · Entity 39180 | SaleCommon Stock | 255,224 | $26.70 | $6,814,480.80 |
DisclosureSEC source: 0000899243-19-008526 · doc4.xml · nonDerivative · entry 1 SVLSF IV, LLC · CIK 0001422339 · 10% owner SV Life Sciences Fund IV (GP), L.P. · CIK 0001422340 · 10% owner SV LIFE SCIENCES FUND IV STRATEGIC PARTNERS, L. P. · CIK 0001392309 · 10% owner SV LIFE SCIENCES FUND IV, L.P. · CIK 0001367381 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,936,352 F1 · ownership.direct: These shares are held directly by SVLS IV LP. F2 · ownership.direct: SVLS IV LP and Strategic Partners (each a "Fund", or collectively the "Funds") may be deemed to beneficially own the shares held by each other Fund because of certain contractual relationships among the Funds and their affiliares. The Funds disclaim beneficial ownership of shares held by any other Fund except to the extent of any pecuniary interest therein. SVLS IV GP, the general partner of the Funds, may be deemed to share voting and dispositive power over the shares held by the Funds. SVLS IV GP disclaims beneficial ownership of shares held by the Funds, except to the extent of any pecuniary interest therein. SVLSF IV, LLC, the general partner of SVLS IV GP. may be deemed to share voting and dispositive power over the shares held by the Funds. SVLSF IV, LLC. disclaims beneficial ownership of shares held by the Funds except to the extent of any pecuniary interest therein. Read SEC document |
| March 05, 2019 Filed Mar 6, 2019 09:05 UTC | KalVista Pharmaceuticals, Inc. KALV · Entity 39180 | SaleCommon Stock | 893 | $23.04 | $20,571.59 |
DisclosureSEC source: 0000899243-19-006369 · doc4.xml · nonDerivative · entry 4 SVLSF IV, LLC · CIK 0001422339 · 10% owner SV Life Sciences Fund IV (GP), L.P. · CIK 0001422340 · 10% owner SV LIFE SCIENCES FUND IV STRATEGIC PARTNERS, L. P. · CIK 0001392309 · 10% owner SV LIFE SCIENCES FUND IV, L.P. · CIK 0001367381 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,219 F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.52 to $23.34, inclusive. The Reporting Persons undertake to provide to Registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.direct: SVLS IV LP and Strategic Partners (each a "Fund", or collectively the "Funds") may be deemed to beneficially own the shares held by each other Fund because of certain contractual relationships among the Funds and their affiliares. The Funds disclaim beneficial ownership of shares held by any other Fund except to the extent of any pecuniary interest therein. SVLS IV GP, the general partner of the Funds, may be deemed to share voting and dispositive power over the shares held by the Funds. SVLS IV GP disclaims beneficial ownership of shares held by the Funds, except to the extent of any pecuniary interest therein. SVLSF IV, LLC, the general partner of SVLS IV GP. may be deemed to share voting and dispositive power over the shares held by the Funds. SVLSF IV, LLC. disclaims beneficial ownership of shares held by the Funds except to the extent of any pecuniary interest therein. F4 · ownership.direct: These shares are held directly by Strategic Partners. Read SEC document |
| March 05, 2019 Filed Mar 6, 2019 09:05 UTC | KalVista Pharmaceuticals, Inc. KALV · Entity 39180 | SaleCommon Stock | 31,439 | $23.04 | $724,244.52 |
DisclosureSEC source: 0000899243-19-006369 · doc4.xml · nonDerivative · entry 3 SVLSF IV, LLC · CIK 0001422339 · 10% owner SV Life Sciences Fund IV (GP), L.P. · CIK 0001422340 · 10% owner SV LIFE SCIENCES FUND IV STRATEGIC PARTNERS, L. P. · CIK 0001392309 · 10% owner SV LIFE SCIENCES FUND IV, L.P. · CIK 0001367381 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,191,576 F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.52 to $23.34, inclusive. The Reporting Persons undertake to provide to Registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.direct: These shares are held directly by SVLS IV LP. F3 · ownership.direct: SVLS IV LP and Strategic Partners (each a "Fund", or collectively the "Funds") may be deemed to beneficially own the shares held by each other Fund because of certain contractual relationships among the Funds and their affiliares. The Funds disclaim beneficial ownership of shares held by any other Fund except to the extent of any pecuniary interest therein. SVLS IV GP, the general partner of the Funds, may be deemed to share voting and dispositive power over the shares held by the Funds. SVLS IV GP disclaims beneficial ownership of shares held by the Funds, except to the extent of any pecuniary interest therein. SVLSF IV, LLC, the general partner of SVLS IV GP. may be deemed to share voting and dispositive power over the shares held by the Funds. SVLSF IV, LLC. disclaims beneficial ownership of shares held by the Funds except to the extent of any pecuniary interest therein. Read SEC document |
| March 04, 2019 Filed Mar 6, 2019 09:05 UTC | KalVista Pharmaceuticals, Inc. KALV · Entity 39180 | SaleCommon Stock | 1,197 | $22.91 | $27,419.68 |
DisclosureSEC source: 0000899243-19-006369 · doc4.xml · nonDerivative · entry 2 SVLSF IV, LLC · CIK 0001422339 · 10% owner SV Life Sciences Fund IV (GP), L.P. · CIK 0001422340 · 10% owner SV LIFE SCIENCES FUND IV STRATEGIC PARTNERS, L. P. · CIK 0001392309 · 10% owner SV LIFE SCIENCES FUND IV, L.P. · CIK 0001367381 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,112 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.02 to $23.02, inclusive. The Reporting Persons undertake to provide to the Registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.direct: SVLS IV LP and Strategic Partners (each a "Fund", or collectively the "Funds") may be deemed to beneficially own the shares held by each other Fund because of certain contractual relationships among the Funds and their affiliares. The Funds disclaim beneficial ownership of shares held by any other Fund except to the extent of any pecuniary interest therein. SVLS IV GP, the general partner of the Funds, may be deemed to share voting and dispositive power over the shares held by the Funds. SVLS IV GP disclaims beneficial ownership of shares held by the Funds, except to the extent of any pecuniary interest therein. SVLSF IV, LLC, the general partner of SVLS IV GP. may be deemed to share voting and dispositive power over the shares held by the Funds. SVLSF IV, LLC. disclaims beneficial ownership of shares held by the Funds except to the extent of any pecuniary interest therein. F4 · ownership.direct: These shares are held directly by Strategic Partners. Read SEC document |
| March 04, 2019 Filed Mar 6, 2019 09:05 UTC | KalVista Pharmaceuticals, Inc. KALV · Entity 39180 | SaleCommon Stock | 42,181 | $22.91 | $966,240.17 |
DisclosureSEC source: 0000899243-19-006369 · doc4.xml · nonDerivative · entry 1 SVLSF IV, LLC · CIK 0001422339 · 10% owner SV Life Sciences Fund IV (GP), L.P. · CIK 0001422340 · 10% owner SV LIFE SCIENCES FUND IV STRATEGIC PARTNERS, L. P. · CIK 0001392309 · 10% owner SV LIFE SCIENCES FUND IV, L.P. · CIK 0001367381 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,223,015 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.02 to $23.02, inclusive. The Reporting Persons undertake to provide to the Registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.direct: These shares are held directly by SVLS IV LP. F3 · ownership.direct: SVLS IV LP and Strategic Partners (each a "Fund", or collectively the "Funds") may be deemed to beneficially own the shares held by each other Fund because of certain contractual relationships among the Funds and their affiliares. The Funds disclaim beneficial ownership of shares held by any other Fund except to the extent of any pecuniary interest therein. SVLS IV GP, the general partner of the Funds, may be deemed to share voting and dispositive power over the shares held by the Funds. SVLS IV GP disclaims beneficial ownership of shares held by the Funds, except to the extent of any pecuniary interest therein. SVLSF IV, LLC, the general partner of SVLS IV GP. may be deemed to share voting and dispositive power over the shares held by the Funds. SVLSF IV, LLC. disclaims beneficial ownership of shares held by the Funds except to the extent of any pecuniary interest therein. Read SEC document |
| February 21, 2019 Filed Feb 21, 2019 14:35 UTC | KalVista Pharmaceuticals, Inc. KALV · Entity 39180 | SaleCommon Stock | 4,764 | $20.60 | $98,138.40 |
DisclosureSEC source: 0000899243-19-004359 · doc4.xml · nonDerivative · entry 6 SVLSF IV, LLC · CIK 0001422339 · 10% owner SV Life Sciences Fund IV (GP), L.P. · CIK 0001422340 · 10% owner SV LIFE SCIENCES FUND IV STRATEGIC PARTNERS, L. P. · CIK 0001392309 · 10% owner SV LIFE SCIENCES FUND IV, L.P. · CIK 0001367381 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,309 F3 · ownership.direct: SVLS IV LP and Strategic Partners (each a "Fund", or collectively the "Funds") may be deemed to beneficially own the shares held by each other Fund because of certain contractual relationships among the Funds and their affiliares. The Funds disclaim beneficial ownership of shares held by any other Fund except to the extent of any pecuniary interest therein. SVLS IV GP, the general partner of the Funds, may be deemed to share voting and dispositive power over the shares held by the Funds. SVLS IV GP disclaims beneficial ownership of shares held by the Funds, except to the extent of any pecuniary interest therein. SVLSF IV, LLC, the general partner of SVLS IV GP. may be deemed to share voting and dispositive power over the shares held by the Funds. SVLSF IV, LLC. disclaims beneficial ownership of shares held by the Funds except to the extent of any pecuniary interest therein. F4 · ownership.direct: These shares are held directly by Strategic Partners. Read SEC document |
| February 21, 2019 Filed Feb 21, 2019 14:35 UTC | KalVista Pharmaceuticals, Inc. KALV · Entity 39180 | SaleCommon Stock | 167,779 | $20.60 | $3,456,247.40 |
DisclosureSEC source: 0000899243-19-004359 · doc4.xml · nonDerivative · entry 5 SVLSF IV, LLC · CIK 0001422339 · 10% owner SV Life Sciences Fund IV (GP), L.P. · CIK 0001422340 · 10% owner SV LIFE SCIENCES FUND IV STRATEGIC PARTNERS, L. P. · CIK 0001392309 · 10% owner SV LIFE SCIENCES FUND IV, L.P. · CIK 0001367381 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,265,196 F2 · ownership.direct: These shares are held directly by SVLS IV LP. F3 · ownership.direct: SVLS IV LP and Strategic Partners (each a "Fund", or collectively the "Funds") may be deemed to beneficially own the shares held by each other Fund because of certain contractual relationships among the Funds and their affiliares. The Funds disclaim beneficial ownership of shares held by any other Fund except to the extent of any pecuniary interest therein. SVLS IV GP, the general partner of the Funds, may be deemed to share voting and dispositive power over the shares held by the Funds. SVLS IV GP disclaims beneficial ownership of shares held by the Funds, except to the extent of any pecuniary interest therein. SVLSF IV, LLC, the general partner of SVLS IV GP. may be deemed to share voting and dispositive power over the shares held by the Funds. SVLSF IV, LLC. disclaims beneficial ownership of shares held by the Funds except to the extent of any pecuniary interest therein. Read SEC document |
| February 20, 2019 Filed Feb 21, 2019 14:35 UTC | KalVista Pharmaceuticals, Inc. KALV · Entity 39180 | SaleCommon Stock | 641 | $20.02 | $12,830.19 |
DisclosureSEC source: 0000899243-19-004359 · doc4.xml · nonDerivative · entry 4 SVLSF IV, LLC · CIK 0001422339 · 10% owner SV Life Sciences Fund IV (GP), L.P. · CIK 0001422340 · 10% owner SV LIFE SCIENCES FUND IV STRATEGIC PARTNERS, L. P. · CIK 0001392309 · 10% owner SV LIFE SCIENCES FUND IV, L.P. · CIK 0001367381 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,073 F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.115, inclusive. The Reporting Persons undertake to provide to Registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.direct: SVLS IV LP and Strategic Partners (each a "Fund", or collectively the "Funds") may be deemed to beneficially own the shares held by each other Fund because of certain contractual relationships among the Funds and their affiliares. The Funds disclaim beneficial ownership of shares held by any other Fund except to the extent of any pecuniary interest therein. SVLS IV GP, the general partner of the Funds, may be deemed to share voting and dispositive power over the shares held by the Funds. SVLS IV GP disclaims beneficial ownership of shares held by the Funds, except to the extent of any pecuniary interest therein. SVLSF IV, LLC, the general partner of SVLS IV GP. may be deemed to share voting and dispositive power over the shares held by the Funds. SVLSF IV, LLC. disclaims beneficial ownership of shares held by the Funds except to the extent of any pecuniary interest therein. F4 · ownership.direct: These shares are held directly by Strategic Partners. Read SEC document |
| February 20, 2019 Filed Feb 21, 2019 14:35 UTC | KalVista Pharmaceuticals, Inc. KALV · Entity 39180 | SaleCommon Stock | 22,594 | $20.02 | $452,239.24 |
DisclosureSEC source: 0000899243-19-004359 · doc4.xml · nonDerivative · entry 3 SVLSF IV, LLC · CIK 0001422339 · 10% owner SV Life Sciences Fund IV (GP), L.P. · CIK 0001422340 · 10% owner SV LIFE SCIENCES FUND IV STRATEGIC PARTNERS, L. P. · CIK 0001392309 · 10% owner SV LIFE SCIENCES FUND IV, L.P. · CIK 0001367381 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,432,975 F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.115, inclusive. The Reporting Persons undertake to provide to Registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.direct: These shares are held directly by SVLS IV LP. F3 · ownership.direct: SVLS IV LP and Strategic Partners (each a "Fund", or collectively the "Funds") may be deemed to beneficially own the shares held by each other Fund because of certain contractual relationships among the Funds and their affiliares. The Funds disclaim beneficial ownership of shares held by any other Fund except to the extent of any pecuniary interest therein. SVLS IV GP, the general partner of the Funds, may be deemed to share voting and dispositive power over the shares held by the Funds. SVLS IV GP disclaims beneficial ownership of shares held by the Funds, except to the extent of any pecuniary interest therein. SVLSF IV, LLC, the general partner of SVLS IV GP. may be deemed to share voting and dispositive power over the shares held by the Funds. SVLSF IV, LLC. disclaims beneficial ownership of shares held by the Funds except to the extent of any pecuniary interest therein. Read SEC document |
| February 19, 2019 Filed Feb 21, 2019 14:35 UTC | KalVista Pharmaceuticals, Inc. KALV · Entity 39180 | SaleCommon Stock | 508 | $20.73 | $10,532.26 |
DisclosureSEC source: 0000899243-19-004359 · doc4.xml · nonDerivative · entry 2 SVLSF IV, LLC · CIK 0001422339 · 10% owner SV Life Sciences Fund IV (GP), L.P. · CIK 0001422340 · 10% owner SV LIFE SCIENCES FUND IV STRATEGIC PARTNERS, L. P. · CIK 0001392309 · 10% owner SV LIFE SCIENCES FUND IV, L.P. · CIK 0001367381 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,714 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.04 to $21.61, inclusive. The Reporting Persons undertake to provide to the Registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.direct: SVLS IV LP and Strategic Partners (each a "Fund", or collectively the "Funds") may be deemed to beneficially own the shares held by each other Fund because of certain contractual relationships among the Funds and their affiliares. The Funds disclaim beneficial ownership of shares held by any other Fund except to the extent of any pecuniary interest therein. SVLS IV GP, the general partner of the Funds, may be deemed to share voting and dispositive power over the shares held by the Funds. SVLS IV GP disclaims beneficial ownership of shares held by the Funds, except to the extent of any pecuniary interest therein. SVLSF IV, LLC, the general partner of SVLS IV GP. may be deemed to share voting and dispositive power over the shares held by the Funds. SVLSF IV, LLC. disclaims beneficial ownership of shares held by the Funds except to the extent of any pecuniary interest therein. F4 · ownership.direct: These shares are held directly by Strategic Partners. Read SEC document |
| February 19, 2019 Filed Feb 21, 2019 14:35 UTC | KalVista Pharmaceuticals, Inc. KALV · Entity 39180 | SaleCommon Stock | 17,912 | $20.73 | $371,365.91 |
DisclosureSEC source: 0000899243-19-004359 · doc4.xml · nonDerivative · entry 1 SVLSF IV, LLC · CIK 0001422339 · 10% owner SV Life Sciences Fund IV (GP), L.P. · CIK 0001422340 · 10% owner SV LIFE SCIENCES FUND IV STRATEGIC PARTNERS, L. P. · CIK 0001392309 · 10% owner SV LIFE SCIENCES FUND IV, L.P. · CIK 0001367381 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,455,569 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.04 to $21.61, inclusive. The Reporting Persons undertake to provide to the Registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.direct: These shares are held directly by SVLS IV LP. F3 · ownership.direct: SVLS IV LP and Strategic Partners (each a "Fund", or collectively the "Funds") may be deemed to beneficially own the shares held by each other Fund because of certain contractual relationships among the Funds and their affiliares. The Funds disclaim beneficial ownership of shares held by any other Fund except to the extent of any pecuniary interest therein. SVLS IV GP, the general partner of the Funds, may be deemed to share voting and dispositive power over the shares held by the Funds. SVLS IV GP disclaims beneficial ownership of shares held by the Funds, except to the extent of any pecuniary interest therein. SVLSF IV, LLC, the general partner of SVLS IV GP. may be deemed to share voting and dispositive power over the shares held by the Funds. SVLSF IV, LLC. disclaims beneficial ownership of shares held by the Funds except to the extent of any pecuniary interest therein. Read SEC document |
| January 07, 2019 Filed Jan 7, 2019 17:12 UTC | KalVista Pharmaceuticals, Inc. KALV · Entity 39180 | SaleCommon Stock | 72 | $20.41 | $1,469.66 |
DisclosureSEC source: 0000899243-19-000686 · doc4.xml · nonDerivative · entry 4 SVLSF IV, LLC · CIK 0001422339 · 10% owner SV Life Sciences Fund IV (GP), L.P. · CIK 0001422340 · 10% owner SV LIFE SCIENCES FUND IV STRATEGIC PARTNERS, L. P. · CIK 0001392309 · 10% owner SV LIFE SCIENCES FUND IV, L.P. · CIK 0001367381 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,222 F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.25 to $20.82, inclusive. The Reporting Persons undertake to provide to Registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.direct: SVLS IV LP and Strategic Partners (each a "Fund", or collectively the "Funds") may be deemed to beneficially own the shares held by each other Fund because of certain contractual relationships among the Funds and their affiliares. The Funds disclaim beneficial ownership of shares held by any other Fund except to the extent of any pecuniary interest therein. SVLS IV GP, the general partner of the Funds, may be deemed to share voting and dispositive power over the shares held by the Funds. SVLS IV GP disclaims beneficial ownership of shares held by the Funds, except to the extent of any pecuniary interest therein. SVLSF IV, LLC, the general partner of SVLS IV GP. may be deemed to share voting and dispositive power over the shares held by the Funds. SVLSF IV, LLC. disclaims beneficial ownership of shares held by the Funds except to the extent of any pecuniary interest therein. F4 · ownership.direct: These shares are held directly by Strategic Partners. Read SEC document |
| January 07, 2019 Filed Jan 7, 2019 17:12 UTC | KalVista Pharmaceuticals, Inc. KALV · Entity 39180 | SaleCommon Stock | 2,527 | $20.41 | $51,581.12 |
DisclosureSEC source: 0000899243-19-000686 · doc4.xml · nonDerivative · entry 3 SVLSF IV, LLC · CIK 0001422339 · 10% owner SV Life Sciences Fund IV (GP), L.P. · CIK 0001422340 · 10% owner SV LIFE SCIENCES FUND IV STRATEGIC PARTNERS, L. P. · CIK 0001392309 · 10% owner SV LIFE SCIENCES FUND IV, L.P. · CIK 0001367381 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,473,481 F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.25 to $20.82, inclusive. The Reporting Persons undertake to provide to Registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.direct: These shares are held directly by SVLS IV LP. F3 · ownership.direct: SVLS IV LP and Strategic Partners (each a "Fund", or collectively the "Funds") may be deemed to beneficially own the shares held by each other Fund because of certain contractual relationships among the Funds and their affiliares. The Funds disclaim beneficial ownership of shares held by any other Fund except to the extent of any pecuniary interest therein. SVLS IV GP, the general partner of the Funds, may be deemed to share voting and dispositive power over the shares held by the Funds. SVLS IV GP disclaims beneficial ownership of shares held by the Funds, except to the extent of any pecuniary interest therein. SVLSF IV, LLC, the general partner of SVLS IV GP. may be deemed to share voting and dispositive power over the shares held by the Funds. SVLSF IV, LLC. disclaims beneficial ownership of shares held by the Funds except to the extent of any pecuniary interest therein. Read SEC document |
| January 03, 2019 Filed Jan 7, 2019 17:12 UTC | KalVista Pharmaceuticals, Inc. KALV · Entity 39180 | SaleCommon Stock | 47 | $20.01 | $940.61 |
DisclosureSEC source: 0000899243-19-000686 · doc4.xml · nonDerivative · entry 2 SVLSF IV, LLC · CIK 0001422339 · 10% owner SV Life Sciences Fund IV (GP), L.P. · CIK 0001422340 · 10% owner SV LIFE SCIENCES FUND IV STRATEGIC PARTNERS, L. P. · CIK 0001392309 · 10% owner SV LIFE SCIENCES FUND IV, L.P. · CIK 0001367381 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,294 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.04, inclusive. The Reporting Persons undertake to provide to the Registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.direct: SVLS IV LP and Strategic Partners (each a "Fund", or collectively the "Funds") may be deemed to beneficially own the shares held by each other Fund because of certain contractual relationships among the Funds and their affiliares. The Funds disclaim beneficial ownership of shares held by any other Fund except to the extent of any pecuniary interest therein. SVLS IV GP, the general partner of the Funds, may be deemed to share voting and dispositive power over the shares held by the Funds. SVLS IV GP disclaims beneficial ownership of shares held by the Funds, except to the extent of any pecuniary interest therein. SVLSF IV, LLC, the general partner of SVLS IV GP. may be deemed to share voting and dispositive power over the shares held by the Funds. SVLSF IV, LLC. disclaims beneficial ownership of shares held by the Funds except to the extent of any pecuniary interest therein. F4 · ownership.direct: These shares are held directly by Strategic Partners. Read SEC document |
| January 03, 2019 Filed Jan 7, 2019 17:12 UTC | KalVista Pharmaceuticals, Inc. KALV · Entity 39180 | SaleCommon Stock | 1,653 | $20.01 | $33,081.49 |
DisclosureSEC source: 0000899243-19-000686 · doc4.xml · nonDerivative · entry 1 SVLSF IV, LLC · CIK 0001422339 · 10% owner SV Life Sciences Fund IV (GP), L.P. · CIK 0001422340 · 10% owner SV LIFE SCIENCES FUND IV STRATEGIC PARTNERS, L. P. · CIK 0001392309 · 10% owner SV LIFE SCIENCES FUND IV, L.P. · CIK 0001367381 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,476,008 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.04, inclusive. The Reporting Persons undertake to provide to the Registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.direct: These shares are held directly by SVLS IV LP. F3 · ownership.direct: SVLS IV LP and Strategic Partners (each a "Fund", or collectively the "Funds") may be deemed to beneficially own the shares held by each other Fund because of certain contractual relationships among the Funds and their affiliares. The Funds disclaim beneficial ownership of shares held by any other Fund except to the extent of any pecuniary interest therein. SVLS IV GP, the general partner of the Funds, may be deemed to share voting and dispositive power over the shares held by the Funds. SVLS IV GP disclaims beneficial ownership of shares held by the Funds, except to the extent of any pecuniary interest therein. SVLSF IV, LLC, the general partner of SVLS IV GP. may be deemed to share voting and dispositive power over the shares held by the Funds. SVLSF IV, LLC. disclaims beneficial ownership of shares held by the Funds except to the extent of any pecuniary interest therein. Read SEC document |
| January 02, 2019 Filed Jan 2, 2019 19:10 UTC | KalVista Pharmaceuticals, Inc. KALV · Entity 39180 | SaleCommon Stock | 6 | $20.00 | $120.00 |
DisclosureSEC source: 0000899243-19-000172 · doc4.xml · nonDerivative · entry 6 SVLSF IV, LLC · CIK 0001422339 · 10% owner SV Life Sciences Fund IV (GP), L.P. · CIK 0001422340 · 10% owner SV LIFE SCIENCES FUND IV STRATEGIC PARTNERS, L. P. · CIK 0001392309 · 10% owner SV LIFE SCIENCES FUND IV, L.P. · CIK 0001367381 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,341 F3 · ownership.direct: SVLS IV LP and Strategic Partners (each a "Fund", or collectively the "Funds") may be deemed to beneficially own the shares held by each other Fund because of certain contractual relationships among the Funds and their affiliates. The Funds disclaim beneficial ownership of shares held by any other Fund except to the extent of any pecuniary interest therein. SVLS IV GP, the general partner of the Funds, may be deemed to share voting and dispositive power over the shares held by the Funds. SVLS IV GP disclaims beneficial ownership of shares held by the Funds, except to the extent of any pecuniary interest therein. SVLSF IV, LLC, the general partner of SVLS IV GP, may be deemed to share voting and dispositive power over the shares held by the Funds. SVLSF IV, LLC disclaims beneficial ownership of shares held by the Funds except to the extent of any pecuniary interest therein. F4 · ownership.direct: These shares are held directly by Strategic Partners. Read SEC document |
| January 02, 2019 Filed Jan 2, 2019 19:10 UTC | KalVista Pharmaceuticals, Inc. KALV · Entity 39180 | SaleCommon Stock | 194 | $20.00 | $3,880.00 |
DisclosureSEC source: 0000899243-19-000172 · doc4.xml · nonDerivative · entry 5 SVLSF IV, LLC · CIK 0001422339 · 10% owner SV Life Sciences Fund IV (GP), L.P. · CIK 0001422340 · 10% owner SV LIFE SCIENCES FUND IV STRATEGIC PARTNERS, L. P. · CIK 0001392309 · 10% owner SV LIFE SCIENCES FUND IV, L.P. · CIK 0001367381 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,477,661 F2 · ownership.direct: These shares are held directly by SVLS IV LP. F3 · ownership.direct: SVLS IV LP and Strategic Partners (each a "Fund", or collectively the "Funds") may be deemed to beneficially own the shares held by each other Fund because of certain contractual relationships among the Funds and their affiliates. The Funds disclaim beneficial ownership of shares held by any other Fund except to the extent of any pecuniary interest therein. SVLS IV GP, the general partner of the Funds, may be deemed to share voting and dispositive power over the shares held by the Funds. SVLS IV GP disclaims beneficial ownership of shares held by the Funds, except to the extent of any pecuniary interest therein. SVLSF IV, LLC, the general partner of SVLS IV GP, may be deemed to share voting and dispositive power over the shares held by the Funds. SVLSF IV, LLC disclaims beneficial ownership of shares held by the Funds except to the extent of any pecuniary interest therein. Read SEC document |
| December 31, 2018 Filed Jan 2, 2019 19:10 UTC | KalVista Pharmaceuticals, Inc. KALV · Entity 39180 | SaleCommon Stock | 702 | $20.00 | $14,042.81 |
DisclosureSEC source: 0000899243-19-000172 · doc4.xml · nonDerivative · entry 4 SVLSF IV, LLC · CIK 0001422339 · 10% owner SV Life Sciences Fund IV (GP), L.P. · CIK 0001422340 · 10% owner SV LIFE SCIENCES FUND IV STRATEGIC PARTNERS, L. P. · CIK 0001392309 · 10% owner SV LIFE SCIENCES FUND IV, L.P. · CIK 0001367381 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,347 F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.32, inclusive. The Reporting Persons undertake to provide to the Registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.direct: SVLS IV LP and Strategic Partners (each a "Fund", or collectively the "Funds") may be deemed to beneficially own the shares held by each other Fund because of certain contractual relationships among the Funds and their affiliates. The Funds disclaim beneficial ownership of shares held by any other Fund except to the extent of any pecuniary interest therein. SVLS IV GP, the general partner of the Funds, may be deemed to share voting and dispositive power over the shares held by the Funds. SVLS IV GP disclaims beneficial ownership of shares held by the Funds, except to the extent of any pecuniary interest therein. SVLSF IV, LLC, the general partner of SVLS IV GP, may be deemed to share voting and dispositive power over the shares held by the Funds. SVLSF IV, LLC disclaims beneficial ownership of shares held by the Funds except to the extent of any pecuniary interest therein. F4 · ownership.direct: These shares are held directly by Strategic Partners. Read SEC document |
| December 31, 2018 Filed Jan 2, 2019 19:10 UTC | KalVista Pharmaceuticals, Inc. KALV · Entity 39180 | SaleCommon Stock | 24,716 | $20.00 | $494,418.86 |
DisclosureSEC source: 0000899243-19-000172 · doc4.xml · nonDerivative · entry 3 SVLSF IV, LLC · CIK 0001422339 · 10% owner SV Life Sciences Fund IV (GP), L.P. · CIK 0001422340 · 10% owner SV LIFE SCIENCES FUND IV STRATEGIC PARTNERS, L. P. · CIK 0001392309 · 10% owner SV LIFE SCIENCES FUND IV, L.P. · CIK 0001367381 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,477,855 F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.32, inclusive. The Reporting Persons undertake to provide to the Registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.direct: These shares are held directly by SVLS IV LP. F3 · ownership.direct: SVLS IV LP and Strategic Partners (each a "Fund", or collectively the "Funds") may be deemed to beneficially own the shares held by each other Fund because of certain contractual relationships among the Funds and their affiliates. The Funds disclaim beneficial ownership of shares held by any other Fund except to the extent of any pecuniary interest therein. SVLS IV GP, the general partner of the Funds, may be deemed to share voting and dispositive power over the shares held by the Funds. SVLS IV GP disclaims beneficial ownership of shares held by the Funds, except to the extent of any pecuniary interest therein. SVLSF IV, LLC, the general partner of SVLS IV GP, may be deemed to share voting and dispositive power over the shares held by the Funds. SVLSF IV, LLC disclaims beneficial ownership of shares held by the Funds except to the extent of any pecuniary interest therein. Read SEC document |
| December 28, 2018 Filed Jan 2, 2019 19:10 UTC | KalVista Pharmaceuticals, Inc. KALV · Entity 39180 | SaleCommon Stock | 103 | $20.03 | $2,062.78 |
DisclosureSEC source: 0000899243-19-000172 · doc4.xml · nonDerivative · entry 2 SVLSF IV, LLC · CIK 0001422339 · 10% owner SV Life Sciences Fund IV (GP), L.P. · CIK 0001422340 · 10% owner SV LIFE SCIENCES FUND IV STRATEGIC PARTNERS, L. P. · CIK 0001392309 · 10% owner SV LIFE SCIENCES FUND IV, L.P. · CIK 0001367381 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,049 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.195, inclusive. The Reporting Persons undertake to provide to the Registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.direct: SVLS IV LP and Strategic Partners (each a "Fund", or collectively the "Funds") may be deemed to beneficially own the shares held by each other Fund because of certain contractual relationships among the Funds and their affiliates. The Funds disclaim beneficial ownership of shares held by any other Fund except to the extent of any pecuniary interest therein. SVLS IV GP, the general partner of the Funds, may be deemed to share voting and dispositive power over the shares held by the Funds. SVLS IV GP disclaims beneficial ownership of shares held by the Funds, except to the extent of any pecuniary interest therein. SVLSF IV, LLC, the general partner of SVLS IV GP, may be deemed to share voting and dispositive power over the shares held by the Funds. SVLSF IV, LLC disclaims beneficial ownership of shares held by the Funds except to the extent of any pecuniary interest therein. F4 · ownership.direct: These shares are held directly by Strategic Partners. Read SEC document |
| December 28, 2018 Filed Jan 2, 2019 19:10 UTC | KalVista Pharmaceuticals, Inc. KALV · Entity 39180 | SaleCommon Stock | 3,631 | $20.03 | $72,718.04 |
DisclosureSEC source: 0000899243-19-000172 · doc4.xml · nonDerivative · entry 1 SVLSF IV, LLC · CIK 0001422339 · 10% owner SV Life Sciences Fund IV (GP), L.P. · CIK 0001422340 · 10% owner SV LIFE SCIENCES FUND IV STRATEGIC PARTNERS, L. P. · CIK 0001392309 · 10% owner SV LIFE SCIENCES FUND IV, L.P. · CIK 0001367381 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,502,571 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.195, inclusive. The Reporting Persons undertake to provide to the Registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.direct: These shares are held directly by SVLS IV LP. F3 · ownership.direct: SVLS IV LP and Strategic Partners (each a "Fund", or collectively the "Funds") may be deemed to beneficially own the shares held by each other Fund because of certain contractual relationships among the Funds and their affiliates. The Funds disclaim beneficial ownership of shares held by any other Fund except to the extent of any pecuniary interest therein. SVLS IV GP, the general partner of the Funds, may be deemed to share voting and dispositive power over the shares held by the Funds. SVLS IV GP disclaims beneficial ownership of shares held by the Funds, except to the extent of any pecuniary interest therein. SVLSF IV, LLC, the general partner of SVLS IV GP, may be deemed to share voting and dispositive power over the shares held by the Funds. SVLSF IV, LLC disclaims beneficial ownership of shares held by the Funds except to the extent of any pecuniary interest therein. Read SEC document |
| December 19, 2018 Filed Dec 21, 2018 16:19 UTC | KalVista Pharmaceuticals, Inc. KALV · Entity 39180 | SaleCommon Stock | 59 | $20.02 | $1,181.06 |
DisclosureSEC source: 0000899243-18-031591 · doc4.xml · nonDerivative · entry 2 SVLSF IV, LLC · CIK 0001422339 · 10% owner SV Life Sciences Fund IV (GP), L.P. · CIK 0001422340 · 10% owner SV LIFE SCIENCES FUND IV STRATEGIC PARTNERS, L. P. · CIK 0001392309 · 10% owner SV LIFE SCIENCES FUND IV, L.P. · CIK 0001367381 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,152 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.16, inclusive. The Reporting Persons undertake to provide to the Registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.direct: SVLS IV LP and Strategic Partners (each a "Fund", or collectively the "Funds") may be deemed to beneficially own the shares held by each other Fund because of certain contractual relationships among the Funds and their affiliates. The Funds disclaim beneficial ownership of shares held by any other Fund except to the extent of any pecuniary interest therein. SVLS IV GP, the general partner of the Funds, may be deemed to share voting and dispositive power over the shares held by the Funds. SVLS IV GP disclaims beneficial ownership of shares held by the Funds, except to the extent of any pecuniary interest therein. SVLSF IV, LLC, the general partner of SVLS IV GP, may be deemed to share voting and dispositive power over the shares held by the Funds. SVLSF IV, LLC disclaims beneficial ownership of shares held by the Funds except to the extent of any pecuniary interest therein. F4 · ownership.direct: These shares are held directly by Strategic Partners. Read SEC document |
| December 19, 2018 Filed Dec 21, 2018 16:19 UTC | KalVista Pharmaceuticals, Inc. KALV · Entity 39180 | SaleCommon Stock | 2,077 | $20.02 | $41,577.39 |
DisclosureSEC source: 0000899243-18-031591 · doc4.xml · nonDerivative · entry 1 SVLSF IV, LLC · CIK 0001422339 · 10% owner SV Life Sciences Fund IV (GP), L.P. · CIK 0001422340 · 10% owner SV LIFE SCIENCES FUND IV STRATEGIC PARTNERS, L. P. · CIK 0001392309 · 10% owner SV LIFE SCIENCES FUND IV, L.P. · CIK 0001367381 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,506,202 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.16, inclusive. The Reporting Persons undertake to provide to the Registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.direct: These shares are held directly by SVLS IV LP. F3 · ownership.direct: SVLS IV LP and Strategic Partners (each a "Fund", or collectively the "Funds") may be deemed to beneficially own the shares held by each other Fund because of certain contractual relationships among the Funds and their affiliates. The Funds disclaim beneficial ownership of shares held by any other Fund except to the extent of any pecuniary interest therein. SVLS IV GP, the general partner of the Funds, may be deemed to share voting and dispositive power over the shares held by the Funds. SVLS IV GP disclaims beneficial ownership of shares held by the Funds, except to the extent of any pecuniary interest therein. SVLSF IV, LLC, the general partner of SVLS IV GP, may be deemed to share voting and dispositive power over the shares held by the Funds. SVLSF IV, LLC disclaims beneficial ownership of shares held by the Funds except to the extent of any pecuniary interest therein. Read SEC document |
| January 31, 2017 Filed Feb 2, 2017 16:10 UTC | ENTELLUS MEDICAL INC ENTL · Entity 16119 | SaleCommon Stock, $0.001 par value | 8,501 | $17.00 | $144,517.00 |
DisclosureSEC source: 0001235802-17-000022 · primary_doc.xml · nonDerivative · entry 5 SVLSF IV, LLC · CIK 0001422339 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P. · CIK 0001233315 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P. · CIK 0001233226 · 10% owner SV LIFE SCIENCES FUND IV STRATEGIC PARTNERS, L. P. · CIK 0001392309 · 10% owner SV LIFE SCIENCES FUND IV, L.P. · CIK 0001367381 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P. · CIK 0001172861 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund IV Strategic Disclosed balance after: 50,849 F1 · price: Represents a public offering price of $17.00 per share before underwriting discounts and commissions pursuant to an Underwriting Agreement dated January 25, 2017, which offering closed on January 31, 2017. F4 · ownership.nature: SV Life Sciences Fund IV (GP), L.P. ("Fund IV GP") is the general partner of each of SV Life Sciences Fund IV, L.P. ("Fund IV") and SV Life Sciences Fund IV Strategic Partners, L.P. ("Fund IV Strategic" and together with Fund IV, the "Fund IV Entities"). SVLSF IV, LLC (the "SVLS General Partner") is the general partner of Fund IV GP and, through an investment committee comprised of David Milne (also a member of the Issuer's board of directors), James Garvey, Kate Bingham, Eugene D. Hill, III and Michael Ross controls voting and investment decisions over the Issuer's shares held by the Fund IV Entities by a majority vote. F5 · ownership.nature: Each member of the investment committee of SVLS General Partner disclaims beneficial ownership over the Shares held by the Fund IV Entities except to the extent of any pecuniary interest therein. Each of SVLS General Partner and Fund IV GP disclaim beneficial ownership over the Shares held by the Fund IV Entities except to the extent of their respective pecuniary interest therein. Read SEC document |
| January 31, 2017 Filed Feb 2, 2017 16:10 UTC | ENTELLUS MEDICAL INC ENTL · Entity 16119 | SaleCommon Stock, $0.001 par value | 299,424 | $17.00 | $5,090,208.00 |
DisclosureSEC source: 0001235802-17-000022 · primary_doc.xml · nonDerivative · entry 4 SVLSF IV, LLC · CIK 0001422339 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P. · CIK 0001233315 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P. · CIK 0001233226 · 10% owner SV LIFE SCIENCES FUND IV STRATEGIC PARTNERS, L. P. · CIK 0001392309 · 10% owner SV LIFE SCIENCES FUND IV, L.P. · CIK 0001367381 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P. · CIK 0001172861 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund IV Disclosed balance after: 1,791,070 F1 · price: Represents a public offering price of $17.00 per share before underwriting discounts and commissions pursuant to an Underwriting Agreement dated January 25, 2017, which offering closed on January 31, 2017. F4 · ownership.nature: SV Life Sciences Fund IV (GP), L.P. ("Fund IV GP") is the general partner of each of SV Life Sciences Fund IV, L.P. ("Fund IV") and SV Life Sciences Fund IV Strategic Partners, L.P. ("Fund IV Strategic" and together with Fund IV, the "Fund IV Entities"). SVLSF IV, LLC (the "SVLS General Partner") is the general partner of Fund IV GP and, through an investment committee comprised of David Milne (also a member of the Issuer's board of directors), James Garvey, Kate Bingham, Eugene D. Hill, III and Michael Ross controls voting and investment decisions over the Issuer's shares held by the Fund IV Entities by a majority vote. F5 · ownership.nature: Each member of the investment committee of SVLS General Partner disclaims beneficial ownership over the Shares held by the Fund IV Entities except to the extent of any pecuniary interest therein. Each of SVLS General Partner and Fund IV GP disclaim beneficial ownership over the Shares held by the Fund IV Entities except to the extent of their respective pecuniary interest therein. Read SEC document |
| January 31, 2017 Filed Feb 2, 2017 16:10 UTC | ENTELLUS MEDICAL INC ENTL · Entity 16119 | SaleCommon Stock, $0.001 par value | 2,106 | $17.00 | $35,802.00 |
DisclosureSEC source: 0001235802-17-000022 · primary_doc.xml · nonDerivative · entry 3 SVLSF IV, LLC · CIK 0001422339 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P. · CIK 0001233315 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P. · CIK 0001233226 · 10% owner SV LIFE SCIENCES FUND IV STRATEGIC PARTNERS, L. P. · CIK 0001392309 · 10% owner SV LIFE SCIENCES FUND IV, L.P. · CIK 0001367381 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P. · CIK 0001172861 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By ILSF Strategic Disclosed balance after: 10,424 F1 · price: Represents a public offering price of $17.00 per share before underwriting discounts and commissions pursuant to an Underwriting Agreement dated January 25, 2017, which offering closed on January 31, 2017. F2 · ownership.nature: International Life Sciences Fund III (GP), L.P. ("Fund III GP") is the general partner of each of: (i) International Life Sciences Fund III (LP1), L.P. ("ILSF LP1"), (ii) International Life Sciences Fund III Co-Investment, L.P. ("ILSF Co-Invest") and (iii) International Life Sciences Fund III Strategic Partners, L.P. ("ILSF Strategic" and collectively, the "Fund III Entities"). ILSF III, LLC (the "ILSF General Partner") is the general partner of Fund III GP and, through an investment committee comprised of James Garvey, Kate Bingham, Eugene D. Hill, III and Michael Ross controls voting and investment decisions over the Issuer's shares held by the Fund III Entities by majority vote. F3 · ownership.nature: Each member of the investment committee of ILSF General Partner disclaims beneficial ownership over the Shares held by the Fund III Entities except to the extent of any pecuniary interest therein. Each of ILSF General Partner and Fund III GP disclaim beneficial ownership over the Shares held by the Fund III Entities except to the extent of their respective pecuniary interest therein. Read SEC document |
| January 31, 2017 Filed Feb 2, 2017 16:10 UTC | ENTELLUS MEDICAL INC ENTL · Entity 16119 | SaleCommon Stock, $0.001 par value | 2,615 | $17.00 | $44,455.00 |
DisclosureSEC source: 0001235802-17-000022 · primary_doc.xml · nonDerivative · entry 2 SVLSF IV, LLC · CIK 0001422339 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P. · CIK 0001233315 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P. · CIK 0001233226 · 10% owner SV LIFE SCIENCES FUND IV STRATEGIC PARTNERS, L. P. · CIK 0001392309 · 10% owner SV LIFE SCIENCES FUND IV, L.P. · CIK 0001367381 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P. · CIK 0001172861 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By ILSF Co-Invest Disclosed balance after: 12,947 F1 · price: Represents a public offering price of $17.00 per share before underwriting discounts and commissions pursuant to an Underwriting Agreement dated January 25, 2017, which offering closed on January 31, 2017. F2 · ownership.nature: International Life Sciences Fund III (GP), L.P. ("Fund III GP") is the general partner of each of: (i) International Life Sciences Fund III (LP1), L.P. ("ILSF LP1"), (ii) International Life Sciences Fund III Co-Investment, L.P. ("ILSF Co-Invest") and (iii) International Life Sciences Fund III Strategic Partners, L.P. ("ILSF Strategic" and collectively, the "Fund III Entities"). ILSF III, LLC (the "ILSF General Partner") is the general partner of Fund III GP and, through an investment committee comprised of James Garvey, Kate Bingham, Eugene D. Hill, III and Michael Ross controls voting and investment decisions over the Issuer's shares held by the Fund III Entities by majority vote. F3 · ownership.nature: Each member of the investment committee of ILSF General Partner disclaims beneficial ownership over the Shares held by the Fund III Entities except to the extent of any pecuniary interest therein. Each of ILSF General Partner and Fund III GP disclaim beneficial ownership over the Shares held by the Fund III Entities except to the extent of their respective pecuniary interest therein. Read SEC document |
| January 31, 2017 Filed Feb 2, 2017 16:10 UTC | ENTELLUS MEDICAL INC ENTL · Entity 16119 | SaleCommon Stock, $0.001 par value | 220,431 | $17.00 | $3,747,327.00 |
DisclosureSEC source: 0001235802-17-000022 · primary_doc.xml · nonDerivative · entry 1 SVLSF IV, LLC · CIK 0001422339 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P. · CIK 0001233315 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P. · CIK 0001233226 · 10% owner SV LIFE SCIENCES FUND IV STRATEGIC PARTNERS, L. P. · CIK 0001392309 · 10% owner SV LIFE SCIENCES FUND IV, L.P. · CIK 0001367381 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P. · CIK 0001172861 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By ILSF LP1 Disclosed balance after: 1,091,166 F1 · price: Represents a public offering price of $17.00 per share before underwriting discounts and commissions pursuant to an Underwriting Agreement dated January 25, 2017, which offering closed on January 31, 2017. F2 · ownership.nature: International Life Sciences Fund III (GP), L.P. ("Fund III GP") is the general partner of each of: (i) International Life Sciences Fund III (LP1), L.P. ("ILSF LP1"), (ii) International Life Sciences Fund III Co-Investment, L.P. ("ILSF Co-Invest") and (iii) International Life Sciences Fund III Strategic Partners, L.P. ("ILSF Strategic" and collectively, the "Fund III Entities"). ILSF III, LLC (the "ILSF General Partner") is the general partner of Fund III GP and, through an investment committee comprised of James Garvey, Kate Bingham, Eugene D. Hill, III and Michael Ross controls voting and investment decisions over the Issuer's shares held by the Fund III Entities by majority vote. F3 · ownership.nature: Each member of the investment committee of ILSF General Partner disclaims beneficial ownership over the Shares held by the Fund III Entities except to the extent of any pecuniary interest therein. Each of ILSF General Partner and Fund III GP disclaim beneficial ownership over the Shares held by the Fund III Entities except to the extent of their respective pecuniary interest therein. Read SEC document |
| November 21, 2016 Filed Nov 25, 2016 21:05 UTC | KalVista Pharmaceuticals, Inc. KALV · Entity 39180 | GrantCommon Stock | 71,211 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-16-087888 · doc1.xml · nonDerivative · entry 2 SVLSF IV, LLC · CIK 0001422339 · 10% owner SV Life Sciences Fund IV (GP), L.P. · CIK 0001422340 · 10% owner SV LIFE SCIENCES FUND IV STRATEGIC PARTNERS, L. P. · CIK 0001392309 · 10% owner SV LIFE SCIENCES FUND IV, L.P. · CIK 0001367381 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,211 F4 · price: Received in exchange for 191,091 shares of KalVista Pharmaceuticals, Ltd. Series A Preferred shares and 53,523 shares of Series B Preferred shares in connection with the closing of the Transaction. On the effective date of the Transaction, the closing price of the Company's common stock was $9.38 per share. All numbers give effect to the Reverse Stock Split. Prior to the Reverse Stock Split, the closing price of the Company's common stock was $0.67 per share. F3 · ownership.direct: SVLS IV LP and Strategic Partners (each a "Fund", or collectively the "Funds") may be deemed to beneficially own the shares held by each other Fund because of certain contractual relationships among the Funds and their affiliates. The Funds disclaim beneficial ownership of shares held by any other Fund except to the extent of any pecuniary interest therein. SVLS IV GP, the general partner of SVLS IV LP and Strategic Partners, may be deemed to share voting and dispositive power over the shares held by SVLS IV LP and Strategic Partners. SVLS IV GP disclaims beneficial ownership of shares held by SVLS IV LP and Strategic Partners except to the extent of any pecuniary interest therein. SVLSF IV, LLC, the general partner of SVLS IV GP, may be deemed to share voting and dispositive power over the shares held by SVLS IV LP and Strategic Partners. SVLSF IV, LLC disclaims beneficial ownership of shares held by SVLS IV LP and Strategic Partners except to the extent of any pecuniary interest ther F5 · ownership.direct: These shares are held directly by Strategic Partners. Read SEC document |
| November 21, 2016 Filed Nov 25, 2016 21:05 UTC | KalVista Pharmaceuticals, Inc. KALV · Entity 39180 | GrantCommon Stock | 2,508,279 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-16-087888 · doc1.xml · nonDerivative · entry 1 SVLSF IV, LLC · CIK 0001422339 · 10% owner SV Life Sciences Fund IV (GP), L.P. · CIK 0001422340 · 10% owner SV LIFE SCIENCES FUND IV STRATEGIC PARTNERS, L. P. · CIK 0001392309 · 10% owner SV LIFE SCIENCES FUND IV, L.P. · CIK 0001367381 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,508,279 F1 · price: Received in exchange for 6,730,810 shares of KalVista Pharmaceuticals, Ltd. Series A Preferred shares and 1,885,228 shares of Series B Preferred shares in connection with the closing of the share purchase transaction (the "Transaction") whereby KalVista Pharmaceuticals, Ltd. became a wholly-owned subsidiary of Carbylan Therapeutics, Inc., which changed its name to KalVista Pharmaceuticals, Inc. (the "Company"). On the effective date of the Transaction, the closing price of the Company's common stock was $9.38 per share. All numbers give effect to the 14:1 reverse stock split effected by the Company on November 21, 2016 (the "Reverse Stock Split"). Prior to the reverse stock split, the closing price of the Company's common stock was $0.67 per share. F2 · ownership.direct: These shares are held directly by SVLS IV LP. F3 · ownership.direct: SVLS IV LP and Strategic Partners (each a "Fund", or collectively the "Funds") may be deemed to beneficially own the shares held by each other Fund because of certain contractual relationships among the Funds and their affiliates. The Funds disclaim beneficial ownership of shares held by any other Fund except to the extent of any pecuniary interest therein. SVLS IV GP, the general partner of SVLS IV LP and Strategic Partners, may be deemed to share voting and dispositive power over the shares held by SVLS IV LP and Strategic Partners. SVLS IV GP disclaims beneficial ownership of shares held by SVLS IV LP and Strategic Partners except to the extent of any pecuniary interest therein. SVLSF IV, LLC, the general partner of SVLS IV GP, may be deemed to share voting and dispositive power over the shares held by SVLS IV LP and Strategic Partners. SVLSF IV, LLC disclaims beneficial ownership of shares held by SVLS IV LP and Strategic Partners except to the extent of any pecuniary interest ther Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.